Chemokines are small
proteins that selectively activate and recruit leukocytes to sites of
inflammation. Several of them, including the
CC chemokines RANTES, MIP-1 alpha, MIP-1 beta, MCP-1, and the
CXC chemokines IL-8, GRO-alpha, ENA-78 have been identified in rheumatoid synovium, implicating a potential role for these molecules in
rheumatoid arthritis. We have investigated the expression patterns of
CC chemokine receptors in the joints of mice with
collagen-induced arthritis, a model for human
rheumatoid arthritis. In addition, we have investigated the incidence and severity of
arthritis in mice receiving administration of
MetRANTES, a modified
chemokine which is a nanomolar antagonist of certain
CC chemokine receptors. The
mRNA expression pattern of the
chemokines and their receptors in the joints of arthritic mice was investigated using
reverse transcriptase-PCR and in situ hybridization. An upregulation of the
CC chemokine receptors mCCR1, mCCR2; mCCR3 and mCCR5 was found in the joints from arthritic mice, compared to control animals. In addition,
injections of
MetRANTES reduced the incidence of disease in a dose dependent manner. Furthermore, in
MetRANTES-treated mice that did develop
arthritis a significantly lower severity of disease was observed compared with control animals. Our data clearly demonstrate a role for
CC chemokines and their receptors in inflammatory joint destruction and support the use of
chemokine receptor antagonists as potential tools to control inflammatory diseases such as
rheumatoid arthritis.